12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Redectane regulatory update

Wilex reached an agreement with FDA to conduct a second Phase III trial of Redectane that will evaluate the product's diagnostic performance instead of its effect on clinical outcomes. The decision is in line with a July recommendation from...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >